Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Ciepiela, A. Zawadzka-Krajewska, U. Demkow (Warsaw, Poland). One-year sublingual immunotherapy in asthmatic children do not influence on basophil’s CD203c stimulated and spontaneous expression. Eur Respir J 2013; 42: Suppl. 57, 1122

Member's Comments

No comment yet.

Related content which might interest you: Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Allergen specific immunotherapy: Effect on immunological markers and clinical outcomes in asthmatic children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Benralizumab effect on blood basophil counts in adults with uncontrolled asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The association between clinical features of asthma and impact of one-year sublingual immunotherapy on immunological system of atopic children Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The clinical and biological response to allergen-specific immunotherapy with basophil activation test (BAT) in the atopic diseases Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Serum IL-10 and IL-17 are not related to the efficacy of allergen specific immunotherapy in asthma Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 QGE031 (ligelizumab) is more effective than omalizumab and placebo in inhibiting allergen-induced early asthmatic response: Results from a predictive modeling study Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Bronchial hyperactivity in perimenstrual asthma is higher than in non-PMA asthmatics and correlates with sputum levels of eotaxin and IL-4 Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Elevated blood eosinophil is a risk factor for future exacerbations in asthmatic children Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Levels of cytokines, sCD31 and expression of CD38 in patients with bronchial asthma of various severity out of a disease exacerbation Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Study on sputum differential counts in asthmatics controlled & uncontrolled on inhaled corticosteroids Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Correlation between asthma control and serum levels of IL-33 in atopic asthma Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016